2014
The FDA granted accelerated approval to pembrolizumab (Keytruda) for advanced melanoma on September 4, 2014.
“On September 4th of 2014, the FDA grants accelerated approval to Pembrolizumab, Keytruda for advanced melanoma.”
Topic
11 facts from 2 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
2014
The FDA granted accelerated approval to pembrolizumab (Keytruda) for advanced melanoma on September 4, 2014.
“On September 4th of 2014, the FDA grants accelerated approval to Pembrolizumab, Keytruda for advanced melanoma.”
2018
In 2018 Merck published Keynote 189, which combined Keytruda with chemotherapy in lung cancer patients regardless of PD-L1 status.
“In 2018, Merck publishes the results of their combination trial, Keynote 189. They gave Keytruda and standard of care chemotherapy to all comers”
2026
Bancel said Moderna's randomized Phase 2 melanoma study, presented at ASCO in spring 2026, showed around 50% recurrence-free survival compared with Keytruda alone, five years after treatment.
“our phase two study, which was also randomized against Ketudra alone, so the same type of study, showed that around 50 % of people had recurrence-free survival versus people only getting Ketudra.”
2026
Bancel said Moderna is running a Phase 3 trial in lung cancer and Phase 2 trials in kidney and bladder cancer, combining the treatment with Keytruda.
“we are in phase three for lung. We're in phase two for kidney cancer, bladder cancer.”
2028
Keytruda's original patents begin expiring in 2028, with eight pembrolizumab biosimilars said to be in development.
“The original patents for Keytruda begin expiring in 2028, and there are already eight different Pembro biosimilars in development ready to jump in when it finally does.”
Undated
A 41-patient Johns Hopkins trial tested Keytruda in patients with and without DNA repair-deficient tumors, finding response rates of 40 to 71% in the deficient group.
“set up their own small 41-patient trial to test Keytruda in both patients who had DNA repair-deficient tumors and in patients with normal tumors.”
Undated
After Keynote 24, five-year overall survival for PD-L1-high lung cancer patients on first-line Keytruda was 30%, versus 16% on chemotherapy.
“after Keynote 24, first-line Keytruda monotherapy in PD-L1 high patients, the five-year overall survival rate is 30 % compared to just 16 % on chemo.”
Undated
In the Keynote 6 melanoma trial, 34% of Keytruda patients were alive after 10 years of follow-up.
“In Keynote 6, 34 % of Keytruda patients are alive after 10-year follow-up.”
Undated
MRC Technology, which helped humanize pembrolizumab, sold part of its royalty rights to a private equity fund for about $150 million before Keytruda's sales took off.
“they decided to sell a chunk of their royalty rights off to a private equity fund for about $150 million.”
Undated
Bancel said published Phase 3 data show only about 60% of patients are disease-free five years after Keytruda treatment.
“only 60 % of people are disease-free after five years. If you look at the phase three published data of Ketudra.”
Undated
Bancel said that patients treated with checkpoint inhibitors such as Keytruda commonly develop autoimmune conditions including type 1 diabetes, lupus and Crohn's disease.
“people that get checkpoints, whether it's Ketudra or any other type of checkpoints from other companies, they end up having type 1 diabetes, lupus, Crohn disease, these type of things.”
Episodes